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Abstract 
Background 
Although BRCA1 and BRCA2 mutations account for only ~27% of the familial aggregation of 
ovarian cancer (OvC), no OvC risk prediction model currently exists which consider the 
effects of BRCA1, BRCA2 and other familial factors. Therefore, a currently unresolved 
problem in clinical genetics is how to counsel women with family history of OvC but no 
identifiable BRCA1/2 mutations. 
Methods 
We used data from 1,548 OvC patients and their relatives from a population-based study, 
with known BRCA1/2 mutation status, to investigate OvC genetic susceptibility models, 
using segregation analysis methods.  
Results 
The most parsimonious model included the effects of BRCA1/2 mutations and the residual 
familial aggregation was accounted for by a polygenic component (S.D 1.43,95%CI:1.10-
1.86) reflecting the multiplicative effects of a large number of genes with small contributions 
to the familial risk. We estimated that 1 in 630 individuals carries a BRCA1 mutation and 1 in 
195 carries a BRCA2 mutation. We extended this model to incorporate the explicit effects of 
17 common alleles that are associated with OvC risk. Based on our models, assuming all of 
the susceptibility genes could be identified we estimate that the half of the female population 
at highest genetic risk will account for 92% of all ovarian cancers. 
Conclusion 
The resulting model can be used to obtain the risk of developing OvC on the basis of 
BRCA1/2, explicit family history and common-alleles. This is the first model that accounts 
for all OvC familial aggregation and would be useful in the OvC genetic counselling process.  
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Introduction 
Ovarian cancer is the third most common gynaecological cancer 
[http://www.cancerresearchuk.org/cancer-info/cancerstats/]. It is well-established that OvC 
has a significant genetic component, with the risk to first-degree relatives of OvC patients 
estimated to be approximately three times greater than the risk to women in the general 
population [1, 2]. High-penetrance mutations in BRCA1 and BRCA2 account for ~27% of 
these familial cancers [1] and another 10% are accounted for by rare variants in the MMR 
genes, RAD51C, RAD51D and BRIP1 (http://www.nature.com/icogs/primer/common-
variation-and-heritability-estimates-for-breast-ovarian-and-prostate-cancers/).   
Risk models which incorporate both BRCA1 and BRCA2 mutations, and other sources of 
variation are required to provide accurate estimates of mutation carrier probabilities and 
cancer risk for use in genetic counselling. Existing risk-prediction models for familial OvC 
such as BOADICEA or BRCAPRO [3, 4] assume that all familial aggregation to OvC is due 
to BRCA1 and BRCA2 mutations but this does not reflect our understanding of OvC genetic-
susceptibility.  As a consequence, these models may underestimate OvC risks in women 
without mutations in these genes.  Therefore, how to counsel women with family history of 
OvC, but without BRCA1 or BRCA2 mutations has remained a major unresolved question in 
clinical cancer genetics.   
We have used data from a large, population-based series of cases diagnosed with OvC, the 
Studies of Epidemiology and Risk factors in Cancer Heredity (SEARCH), and segregation 
analysis methods to develop genetic models for OvC that incorporate the effects of BRCA1 
and BRCA2 mutations and model the residual familial aggregation to OvC. The explicit 
effects of seventeen common OvC susceptibility alleles, identified through genome-wide 
association studies (GWAS), were then incorporated into the algorithm. We finally 
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considered the implications of our risk prediction model for OvC risk stratification in the 
general population and its use in OvC prevention. 
 
Material and methods 
Study Population 
We used data on 1548 OvC cases (probands) recruited between 1999-2010, along with 
information on their first and second-degree relatives ascertained through an epidemiological 
questionnaire. The probands were drawn from SEARCH, a large population based study with 
cases ascertained through the Eastern Cancer Registration and Information Centre [1, 5].  
Half-sibling status and  relative-type to the proband, age at cancer diagnosis, cancer site, vital 
status, status-age (the age at death if deceased, the current age if alive) and year-of-birth were 
recorded for all probands and relatives.   
BRCA1 and BRCA2 mutation screening  
SEARCH OvC probands were screened for BRCA1 and BRCA2 mutations as part of a 
separate project to evaluate the contribution of rare, high- and moderate-risk variants to 
overall OvC risk in the general population [6].  Briefly, this involved targeted sequence 
library preparation using multiplexed 48.48 Fluidigm access arrays and sequencing on an 
Illumina HiScan. BRCA1 and BRCA2 mutation status information was available on all 1,548 
probands. The following alterations were considered pathogenic: protein-truncating 
insertion/deletion variants, nonsense mutations, consensus splice-site variants and missense 
variants with reported damaging effect on protein function.  For the purpose of our analysis, 
BRCA1 and BRCA2 mutation status were both recorded simply as mutation-positive or 
negative, with no distinction between different mutation types by location or functional 
effect.  
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Statistical analysis 
Segregation analysis of ovarian cancer  
Complex segregation analysis was used to fit genetic models to the occurrence of OvC in 
families, incorporating the explicit effects of BRCA1 and BRCA2 mutations on OvC risk.  
Female family members were followed from birth until the first of: OvC diagnosis age, age at 
questionnaire, death age or age 80.  We also considered breast cancer occurrence, but 
individuals were continued to be followed up for ovarian cancer after a breast cancer 
diagnosis in the analysis.  Data on risk-reducing surgeries were not available in relatives of 
probands and we were therefore unable to censor at these events.  However, since this is a 
population based study in which women with ovarian cancer diagnosis were recruited soon 
after diagnosis, and participants were not aware of their mutation status at the time of 
recruitment we do not expect a high prevalence of risk-reducing surgeries at the time of 
pedigree collection. 
 
To incorporate the effects of BRCA1 and BRCA2 mutations and to take account of changes in 
cancer incidences over time, the OvC incidence for a female i was assumed to depend on the 
underlying genetic effects through a model of the form 
( ) ( ) ( )iiii PMktGktktg ++= ),(exp,,, 0λλ  where ( )kt,0λ  is the baseline incidence for 
individuals born in birth cohort k and ),( ktGi  is the logarithm of the relative risk associated 
with BRCA1/ BRCA2 mutation status g, for age t and cohort k; iM  is the logarithm of the 
relative risk associated with a third hypothetical major gene and iP  is the polygenic 
component.  iP  is assumed to have a normal distribution with variance 
2σ  and mean zero 
and is approximated by the hypergeometric distribution to make it amenable to 'peeling'[7, 8].  
Eight sets of birth cohort and calendar-period-specific incidences for OvC in the general 
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population were derived on the basis of incidences for England and Wales as described 
previously for the BOADICEA model [9]. The eight cohorts included: individuals born pre-
1920 then in 10-year intervals up to post 1970.  As the number of BRCA1 and BRCA2 
mutation carriers in the SEARCH dataset was too small to obtain reliable cancer risk 
estimates for mutation carriers, we also used external estimates of the ovarian and breast 
cancer relative risks for BRCA1 and BRCA2 carriers relative to population incidences, based 
on some of the largest studies available [10].  Hence, the average BRCA1 and BRCA2 ovarian 
and breast cancer incidences, over all possible genetic effects in the model were fixed. The 
cohort-specific baseline incidences for BRCA1 and BRCA2 carriers, were obtained for each 
cohort separately by constraining the average incidences over all possible genetic effects to 
agree with the external estimates[8].  Similarly, the baseline incidences for non-mutation 
carriers were obtained by constraining the incidences over the BRCA1, BRCA2, other major 
gene and polygenic effects to agree with the population incidences (Supplementary Material; 
Methods). 
 
Since BRCA1 and BRCA2 mutations are also associated with increased breast cancer risks 
[10, 11], we incorporated the effect of these mutations on breast cancer incidence. We 
assumed a similar model for the breast cancer incidence, however the breast cancer incidence 
was assumed to depend on only the effects of BRCA1 and BRCA2 mutations.  
 
In our analyses we considered models with just the BRCA1 and BRCA2 effects, and models 
which additionally included a dominant, recessive or codominant hypothetical major gene, 
and/or a polygenic component. 
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All the families used in the analysis consisted of women ascertained on the basis of OvC.  
Thus, to adjust for ascertainment bias, [12-14] we employed an ascertainment assumption-
free approach in which the likelihood of each family’s joint phenotype was modelled as 
)(
)(
iyP
yP
 where y  is the vector of all the family phenotypes including all phenotypic and 
genotypic information on the proband and yi  is the age, birth-date and ovarian-cancer -only 
phenotype of the proband.  A sensitivity parameter was introduced, giving the probability of 
detecting a mutation if one existed, to take account of the fact that mutation screening 
methods used cannot detect large re-arrangements in BRCA1 and BRCA2 [6]. A fixed value 
of 0.9 for both BRCA1 and BRCA2 was used in all models, but additional sensitivity analyses 
were performed.  
Maximum-likelihood estimates of the gene frequencies, polygenic standard error and the log-
relative-risk for the hypothetical major gene were calculated using pedigree analysis software 
MENDEL [15]. Standard errors for each parameter were obtained from the observed 
information matrix and were used to calculate 95% confidence intervals. To assess goodness-
of-fit, all of the models with a polygenic or major-gene component were compared with the 
baseline model with just BRCA1 and BRCA2 effects using likelihood ratio tests (LRTs). 
Further LRTs were used to test for differences between the fit of nested models and the 
Akaike Information Criterion (AIC) equal to -2(log-likelihood – no. of parameters) was used 
to compare non-nested models.   
 
OvC risk, mutation frequency and carrier numbers prediction 
We used each of the models fitted to predict BRCA1 and BRCA2 mutation carrier frequencies  
and the risk of developing OvC in the future using the methods previously described in [11] 
The predictions were used to compare the fit of the models as part of an internal validation. 
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Although goodness-of-fit tests are not valid using the data generating dataset, we calculated 
chi-squared goodness-of-fit tests that compared the observed and expected number of 
mutations and used these as an indicator of the model fit to the data. The expected number of 
mutation carriers was computed as the sum of the predicted BRCA1 and BRCA2 carrier 
probabilities across all SEARCH families. 
 
We used the most parsimonious model to estimate risk of developing OvC for a 50 year-old 
woman to demonstrate the possible clinical implications for different scenarios of BRCA1 
and BRCA2 carrier status and extent of family history. The results were compared with the 
corresponding predictions from the current BOADICEA model. 
 
Incorporating SNPs into the risk prediction algorithm 
We extended the most parsimonious model to also incorporate the explicit effects of the 
known common ovarian cancer susceptibility alleles following the methodology already 
published in the context of prostate cancer [16].  The residual familial aggregation of OvC 
was accounted for in this model by a polygenic component reflecting the additive effects of a 
large number of genetic variants. The polygenic component iP  for each individual was 
divided into two parts for this purpose; a known-variant polygenic component iKP ,  reflecting 
the Polygenic Risk Score (PRS) due to seventeen SNPs known to be associated with OvC 
[17] and an unknown residual polygenic component iUP , .  The two components were assumed 
to be independent and normally distributed with mean 0 and variance 2Kσ  and 
2
Uσ  
respectively (see details in Supplementary Material; Methods). 2Kσ  was calculated using 
previously described methods [16], based on the known allele frequencies and per-allele 
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Odds Ratio estimates. 2Uσ  is then obtained as the difference between the total polygenic 
variance and variance of the PRS. 
 
Distribution of ovarian cancer risk and implications for ovarian cancer prevention.  
The OvC risk associated with any individual common genetic variant is very small compared 
with rare variants like BRCA1.  However, as there are thought to be many as yet undiscovered 
common variants and their effects are assumed to be additive on the logarithmic scale a 
woman with a high polygenic load is likely to have a greatly increased risk of OvC compared 
with someone with a low polygenic load.  Being able to distinguish between high and low-
risk individuals in the population could be a valuable tool in clinical practice.  Therefore, we 
considered the potential for risk prediction based both on known common variants and the 
total hypothesised polygenotype.  We followed a similar approach to the methods described 
in [18] (see supplementary Material for more details).  We calculated the proportions of the 
population and of cancer cases at different levels of SNP risk and polygenic risk and plotted 
against each other for comparison purposes.  This provides an informative measure of the 
relationship between risk distribution in the population and among cancer cases. In the 
hypothetical future when an individual’s polygenic risk can be estimated with a high degree 
of accuracy, either from family history or because most of the currently theoretical 
polygenotype is accounted for by known variants, these measures could be used to estimate 
what proportions of the population would need to be monitored/screened/followed in order to 
detect a particular percentage of ovarian cancers. This could also potentially contribute to 
stratifying population by OvC risk to enable targeting of effective screening/preventive 
intervention strategies for appropriate risk groups.    
 
Results 
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Data from 1,548 OvC cases recruited into the SEARCH study were used for our analyses. 
Female relatives of probands included 1,340 mothers, 1,404 sisters and 1,144 daughters, of 
whom 80 were also diagnosed with OvC and 191 with breast cancer. The numbers of 
probands and their first-degree relatives, the number of ovarian cancers diagnosed in each 
group and other sample characteristics are summarised in Supplementary Table 1.  All 
probands were screened for BRCA1 and BRCA2 mutations, identifying 44 and 62 carriers 
respectively.  The loci, minor allele frequencies and odds ratios of the 17 SNPs used in 
incorporating their effects into the final model are displayed in Supplementary Table 2.  
 
Segregation analyses for ovarian cancer incorporating the effects of BRCA1 and BRCA2  
mutations  
The results for the seven models that incorporate the explicit effects of BRCA1 and BRCA2 
on OvC risk and which assume cohort-specific incidences are summarised in Table 1.  All the 
seven models which accounted for the residual familial aggregation to OvC (in addition to 
BRCA1 and BRCA2) provided significantly better fit than the model that included only 
BRCA1 and BRCA2 (P-value<2.8x10-5). The worst-fitting model for the residual familial 
aggregation of OvC, other than BRCA1 and BRCA2, was the major recessive and the most 
parsimonious was the polygenic model, with AICs of 5772.244 and 5764.372 respectively. 
Although the mixed models of inheritance all had slightly larger log-likelihoods, they did not 
improve the fit significantly over the model with only a polygenic component in addition to 
the BRCA1 and BRCA2 effects (likelihood ratio test p-values>0.14). In all models that 
included a hypothetical third major gene the relative risk for the susceptible women was very 
high (ranging between ~54 to ~122).  The estimated population allele frequency for BRCA1 
and BRCA2 under the polygenic model were 0.08% (95% CI: 0.06%-0.11%) and 0.26% 
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(95%CI: 0.002%-0.33%) respectively with a standard deviation of the polygenic component 
of 1.43 (95% CI:1.1-1.86) . 
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Table 1: Parameter estimates, goodness-of-fit measures and likelihood ratio tests (LRTs) of the seven cohort-specific models for breast and 
ovarian cancer.
Model BRCA1 frequency 
(95%CI) 
BRCA2 frequency 
(95%CI) 
Major gene frequency 
(95%CI) 
Major gene log 
relative risk 
(95%CI) 
Polygenic 
S.D 
(95%CI) 
Log-
likelihood 
AIC LRT p-value  
 
Base 0.00081  
(0.00061, 0.0011) 
0.0026 
(0.0020,0.0033) 
- - - -2892.237 5788.474 5.11E-06 
 
Major 
dominant 
0.00079 
(0.00060,0.0011) 
0.0026 
(0.0020,0.0032) 
0.00025 
(0.000041,0.0015) 
4.8  
(3.3,6.2) 
- -2880.343 5768.686 0.047 
Major 
recessive 
0.00080 
(0.00060,0.0011) 
0.0026 
(0.0020,0.0032) 
0.085 
 (0.017,0.33) 
4.0 
 (2.0,6.0) 
- -2882.122 5772.244 0.0079 
Major 
general 
0.00079 
(0.00060,0.0011) 
0.0026 
(0.0020,0.0032) 
0.00025 
(0.00020,0.0033) 
4.8 
 (3.3,6.3) 
- -2880.335 5770.67 0.013 
    7.4 
(-14.1,28.8) 
    
Polygenic 0.00079 
(0.00060,0.0011) 
0.0026 
(0.0020,0.0033) 
- - 1.43 
(1.10,1.86) 
-2879.186 5764.372 0.28 
         
Mixed 
dominant 
0.00079 
(0.00059,0.0011) 
0.0026 
(0.0020,0.0032) 
0.00023 
(0.000023,0.0022) 
4.7 
(2.8,6.6) 
1.09 
(0.64,1.86) 
-2877.289 5764.576 0.91 
Mixed 
recessive 
0.00079 
(0.00060,0.0011) 
0.0026 
(0.0020,0.0032) 
0.076 
 (0.020,0.25) 
3.7 
 (1.5,5.9) 
1.19 
(0.74,1.91) 
-2878.374 5768.806 0.14 
Mixed 
general 
0.00079 
(0.00059,0.0011) 
0.0026 
(0.0020,0.0032) 
0.00023 
(0.000023,0.0023) 
4.7 
 (2.8,6.6) 
1.09 
(0.64,1.86) 
-2877.283 5766.566  
    9.4 
(-20.5,39.3) 
    
S.D, standard deviation; AIC, Akaile’s Information Criterion; LRT p-value, probability of the difference between log-likelihoods comparing each model against 
the mixed general model; 
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Predicted number of BRCA1 and BRCA2 mutation carriers and family members 
diagnosed with ovarian cancer.  
The expected numbers of BRCA1 and BRCA2 mutation carriers computed under each of the 
models are displayed in Table 2.  In line with magnitude of the log-likelihoods, all seven 
models gave similar predictions which were noticeably more accurate than the model that did 
not allow for additional residual familial aggregation other than the effects of BRCA1 and 
BRCA2.  The polygenic model performed best for predicting the number of BRCA2 mutation 
carriers and there was a slight improvement in accuracy of BRCA1 number under the mixed 
models.  In comparison, under the current implementation of BOADICEA, the predicted 
BRCA1 numbers were very close to the observed values but the number of BRCA2 carriers 
were substantially under-predicted (p-value for difference between observed and expected 
number of mutations = 4.64E-16). 
 
Similarly, when computing the expected number of families with a mother, a sister or mother 
and sister diagnosed with ovarian cancer, the predicted numbers were closer to the observed 
for the polygenic and mixed models of inheritance (Supplementary Table 3).   
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Table 2: Numbers of mutation carriers predicted by each model and comparison with observed 
numbers. 
 
Model for the 
residual familial 
aggregation 
Observed 
BRCA1  
carriers 
Expected 
BRCA1  
carriers 
Observed 
BRCA2  
carriers 
Expected 
BRCA2  
carriers 
Chi-squared 
value* 
Baseline 44 56.95 62 63.59 2.98 
      
Polygenic  44 49.32 62 61.98 0.57 
      
Dominant major 44 55.62 62 63.08 2.45 
Recessive major 44 55.97 62 63.11 2.58 
General major 44 55.62 62 63.08 2.45 
      
Dominant mixed 44 48.07 62 61.01 0.36 
Recessive mixed 44 49.08 62 61.10 0.54 
General mixed 44 48.05 62 61.02 0.36 
      
BOADICEA 44 45.76 62 23.03 66.01 
*Chi-squared value = value of Chi-squared goodness of fit test. 
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Predicting future ovarian cancer risks. 
We estimated the probabilities of developing OvC for a 50-year-old woman born in 1940, 
with the following family histories: (i) no information on relatives; (ii) having a mother and 
sister cancer-free at ages 65 and 50; (iii) mother and sister diagnosed with OvC at ages 65 
and 50; and (iv and v) with both combinations of one diagnosed and one cancer free at these 
same ages.  We compared these estimates to the risk estimates from the current version of 
BOADICEA. 
Figure 1 displays the probabilities of developing OvC for a 50-year old female without a 
BRCA1 or BRCA2 mutation.  Under the best fitting model, the risk of OvC increases with 
increasing number of relatives diagnosed with OvC. In contrast, the corresponding 
predictions under BOADICEA remain the same under all assumptions about family history. 
Similar patterns are observed when the index female is assumed to carry a BRCA1, or a 
BRCA2 mutation, where the risks in mutation carriers also depend on the exact family history 
information (Supplementary Figures 1 and 2).  Under BOADICEA, the risks in mutation 
carriers are not modified by family history and are all very close to the corresponding risks 
predicted by our polygenic model algorithm for a female with no family history information.  
 
Incorporating common alleles into the model. 
The loci, minor allele frequencies and odds ratios for the 17 SNPs considered are displayed in 
Supplementary Table 2.  Under the assumptions that the effects of the SNPs on OvC are all 
mutually independent and the same for BRCA1 carriers, BRCA2 carriers and non-carriers, 
each observed SNP profile was translated into a polygenic risk score (PRS).  This PRS was 
assumed to have a centralised Normal distribution with a variance of 0.0915, explaining 
about 4.5% of the total polygenic variance in our model.     
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The lifetime risks of OvC to a 20-year-old non BRCA1/2 mutation carrier, conditional on 
known PRS and family history of OvC, are shown in Figure 2.  As expected, the lifetime risk 
of developing OvC rose exponentially with increasing PRS.  For example, the lifetime risk of 
ovarian cancer for a woman without a BRCA1 or BRCA2 mutation, but with two affected 
first degree relatives is predicted to be >5% if she is at the top 50% of the PRS distribution.   
Examples of age specific risks for a 50 year old female at the 5th and 95th percentiles of the 
PRS and by different family history assumptions are shown in Supplementary figures 3-5   
 
Implications of the polygenic model for ovarian cancer prevention. 
For a polygenic log-risk with the standard deviation of 1.434, estimated under the best fitting 
segregation analysis model, and assuming a baseline population OvC risk of 0.02 by age 80, 
the half of the population at higher risk accounts for 92% of all ovarian cancers.  Figure 3 
displays the proportion of the population that have a risk greater than a given level and the 
proportion of the cases predicted to occur within this subgroup. From these curves, it can be 
seen that 50% of all cancers occur in the 7.7% of the population with a risk of 5.6% or more.  
In Figure 4, the population proportions are plotted against the case proportions accounted for, 
for the polygenic log-risk distributions and the combined SNP-effect distributions. The total 
known variance of the effects of 17 known SNPs is 0915.02 =Kσ (see Material and Methods 
and Supplementary Material). Due to the low known variance, the distinction between 
population and case risk is very low for the seventeen SNPs alone.  
 
Discussion 
We used complex segregation analysis to develop a risk-prediction model for familial OvC 
that incorporates the effects of BRCA1 and BRCA2 mutations, family history and several 
newly-established common OvC susceptibility alleles, using data from a population-based 
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study of OvC cases in the UK.  Our model accounts for the familial aggregation of OvC and 
helps inform a major unresolved clinical question on how to counsel women with family 
history of OvC but without BRCA1 or BRCA2 mutations. 
 
The most parsimonious model included the effects of BRCA1 and BRCA2 mutations together 
with a polygenic component. This suggests that most of the familial aggregation not 
accounted for by BRCA1 and BRCA2 consists of the effects of a large number of genetic 
variants, each having small contributions to the OvC familial risk. This is in line with results 
from recent OvC GWAS [19-22] which have demonstrated that common low-risk ovarian 
cancer susceptibility alleles exist. Parallel studies in breast cancer suggested that thousands 
such genetic susceptibility alleles are likely to exist which explain a substantial fraction of the 
unexplained genetic variability [23]. A similar model is likely to apply to ovarian cancer.  A 
model which included an additional, dominantly-inherited, high-penetrance gene had the 
highest likelihood.  Such a model could reflect the joint effects of other rare OvC 
susceptibility variants that confer higher risks collectively.  However, our analysis may be 
underpowered as this model did not fit significantly better than the polygenic model.   
 
Previous OvC segregation analyses [24, 25] that accounted for BRCA1 and BRCA2 mutations 
were based on 10-fold smaller sample set of high-risk OvC families and did not investigate 
polygenic models for the residual familial aggregation of OvC.  In contrast to the present 
study, those studies found no significant evidence of a third high-penetrance gene in addition 
to BRCA1 and BRCA2.  The difference could be explained primarily by the much lower 
power of those analyses, due the smaller sample size, but also due the fact the ascertainment 
adjustment involved conditioning on all family phenotypes which imposed a much greater 
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penalty in comparison to the present analysis which used families selected only on the OvC 
status of the index case.   
 
Under the best-fitting model, the BRCA1 and BRCA2 mutation frequencies were estimated to 
be 0.00079 and 0.0026 respectively, corresponding to a carrier frequency of 1 in 630 
population for BRCA1 and 1 in 195 population for BRCA2. These were higher than the 
BOADICEA estimates of 0.0006 for BRCA1 and 0.001 for BRCA2[10], but the difference 
was significant only for BRCA2 (p-values 0.13 and 0.00002). This was also reflected in the 
significant under-prediction of BRCA2 mutations under the BOADICEA model in the current 
dataset.  This difference between the studies is probably partly due to the data sources and 
differences in the mutation screening techniques.  The 2785 families used to fit the 
BOADICEA algorithm were ascertained primarily through population-based breast cancer 
patients.  This source of difference would be in line with the fact that BOADICEA was found 
to predict BRCA1 and BRCA2 mutations and breast cancer risk well in independent datasets 
of breast cancer families [10, 26-28]. BOADICEA has not been evaluated so far in families 
ascertained on the basis of ovarian cancer only.  Another possible factor is the mutation 
screening methods.  The current study is based on currently available sequencing 
technologies [6]  which are estimated to be more sensitive in detecting mutations than the 
techniques used in the late 1990’s [29].  Moreover, the knowledge of which mutations are 
actually pathogenic has improved substantially over time [30].  Both of these factors could 
contribute to higher mutation frequencies, although it is unclear why the difference is only 
significant for BRCA2. An alternative explanation could be a differential response rate for 
participating in the present study between mutation carriers and non-carriers. BRCA1 and 
BRCA2 mutations have both been associated with improved short-term ovarian cancer 
survival.  In particular, BRCA2 mutation carriers have been reported to have a better 
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prognosis [31, 32]. If women with short prognosis are more likely to participate in the study, 
this could potentially lead to an overestimation of the mutation frequency. However, data on 
response differences by prognostic characteristics are not available to assess this.  
 
 
In the long term we expect that these differences will be resolved by fitting a single algorithm 
to all available data that models comprehensively both the genetic susceptibility to breast and 
ovarian cancer. However, at this stage this is not  feasible based on current technologies due 
to computational complexities  (in particular the number of underlying genotypes in the 
models). The current approach aims to develop separate algorithms for the susceptibility to 
breast and ovarian cancer which  individually incorporate the explicit effects of all observed 
and unobserved genetic variants such that we obtain accurate risks of each cancer. Validation 
studies in independent datasets will determine the most appropriate model for use in each 
context. As technologies evolve over time, in the long-term we expect to synthesise the 
models into a single algorithm.  
 
In our analyses we took account of ovarian cancers occurring after a breast cancer diagnosis, 
assuming the ovarian cancer incidence remains the same before and after the breast cancer 
diagnosis.  Repeating the analysis, but censoring at the first cancer yielded similar results 
(e.g. under the polygenic model BRCA1 mutation frequency was estimated to be 0.083% and 
BRCA2 mutation frequency was 0.27% with a polygenic standard deviation of 1.46). 
Therefore, our results were not sensitive to these assumptions. 
 
In our analysis, we aimed to include only epithelial ovarian cancers. However, subsequent to 
the model fitting process, additional pathology information became available, which revealed 
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41 of the   probands’ tumours to be non-epithelial ovarian cancers. This consisted of one 
BRCA2 carrier and 40 non-carriers, were non-epithelial ovarian cancers. Refitting the models 
using only epithelial ovarian cancers (EOCs) had very little effect on results. Under the 
polygenic model, the estimated BRCA1 and BRCA2 mutation frequencies were 0.081% and 
0.26%, polygenic standard deviation was 1.44 and the estimated numbers of BRCA1 and 
BRCA2 carriers were 48.6 and 60.8 respectively.  
 
Our models assumed that the mutation testing sensitivities were 0.9 for both BRCA1 and 
BRCA2. Obtaining exact estimates is difficult, but in practice mutation sensitivities could be 
lower. We refitted the models using a sensitivity parameter of 0.83 for BRCA1 and 0.76 for 
BRCA2 [6]. Under the polygenic model the estimated BRCA1 and BRCA2 mutation 
frequencies were slightly higher at 0.086% and 0.3% respectively and the polygenic standard 
deviation decreased slightly to 1.375, but none of these were significantly different than the 
results under a sensitivity of 0.9. These patterns are expected as the mutation frequency and 
mutation screening sensitivity parameters are confounded.  
 
One possible source of bias in our analysis is the possibility of errors in the reporting of 
family cancer history.  However, previous studies have found reported OvC history in first-
degree relatives to be reasonably accurate (83.3% probability of agreement between reported 
OvC status in first-degree relatives and established status)[33, 34]. Therefore, the fact that the 
ovarian cancer diagnoses in relatives are not confirmed, is unlikely to have a great impact on 
our results. Another possible weakness of our study is the usage of external estimates of 
breast and OvC relative risks to BRCA1 and BRCA2 mutation carriers.  However, due to the 
small number of mutation carriers in the SEARCH dataset, it was not possible to estimate 
reliably the cancer risks for BRCA1 and BRCA2 mutation carriers.  The estimates used were 
22 
 
based on some of the largest studies available [10, 35]. Future studies should aim to analyse 
all the data jointly.   
 
Under our models, the probabilities of developing OvC increase with the number of ovarian 
cancers in relatives while under BOADICEA [10] the risks remain invariable, at values very 
close to those we predicted for someone with no recorded family history, which for non-
BRCA1 or -BRCA2 carriers is close to the population risk. This is due to the fact that 
BOADICEA, along with other previously developed algorithms such as BRCAPRO [3] use 
only BRCA1 and BRCA2 mutations to model genetic susceptibility to OvC. As a result, under 
BOADICEA and BRCAPRO, OvC risks are determined only by the BRCA1 and BRCA2 
mutation status, no matter what their family history is. Three quarters of OvC familial relative 
risk is not accounted for by BRCA1 and BRCA2 mutations [1], therefore the present models 
are more realistic. As it stands, BOADICEA and BRCAPRO could underestimate the risk to 
many individuals with a family history of OvC but no identified mutations.  
 
In all models incorporating a polygenic component or known SNPS, the effects were 
assumed to be the same for carriers of a BRCA1 or BRCA2 mutation and non-carriers. This 
assumption is supported by recent studies [17, 36, 37] where all but one of the OvC loci 
identified through GWAS were found to be associated with risk to a similar relative extent in 
BRCA1 and BRCA2 carriers and non-carriers [38]. If future studies identify additional 
BRCA1- or BRCA2-specific modifiers of risk it should be possible to extend the present 
model to allow for this level of complexity.  
 
Although we have incorporated the explicit effects of the common low risk alleles, future 
efforts should focus on incorporating the explicit effects of other intermediate risk OvC 
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susceptibility variants such as RAD51C, RAD51D and BRIP1 [39-41]. However, prior to 
incorporating those into risk prediction models it is critical to obtain precise estimates of the 
risks conferred by such mutations which currently are not available. 
 
We also used our models to investigate the possible implications for OvC risk stratification in 
the population. Using the parameters from the polygenic model, we estimate that 50% of 
ovarian cancers occur within the 7.7% of the population at highest risk. Meanwhile, the half 
of the population at lower risk is forecast to contain only one in thirteen of cancer cases. 
Targeting the 10% at highest polygenic risk for preventative measures or excluding the low-
risk half could therefore lead to a much more efficient distribution of resources. However, to 
achieve this will require that we identify all the genetic factors that contribute to polygenic 
inheritance. The almost flat curve in Figure 4 from the SNP log-risk distribution, with the 
50% of the population at higher risk predicted to contain around only 60% of cases, suggests 
very low power to discriminate between high and low risk individuals on SNP profiles alone. 
It is perhaps not surprising as currently only 4.5% of the ovarian cancer polygenic variance is 
accounted for by known low-penetrance genetic variants. However, the currently known SNP 
profiles in combination with family history information and other risk factors for the disease 
are expected to have a greater impact for individualised ovarian cancer risk prediction, as 
demonstrated by our model.   
 
Our model can be used in the genetic counselling process of women with family history of 
ovarian cancer as well as for counselling women both with and without BRCA1 or BRCA2 
mutations. This would be helpful to both BRCA1 and BRCA2 carriers and non-carriers while 
making decisions regarding clinical interventions following counselling.  Probabilities of 
developing OvC based on family history, BRCA1, BRCA2 mutation status and/or polygenic 
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risk could be used to assess the risk to an individual and to discriminate between high and 
low-risk individuals, which may in time prove useful for targeting appropriate interventions.    
 
Future research 
Although the mutation carrier probability algorithms produced very accurate estimates of the 
number of carriers in the SEARCH data, an external validation is needed to establish the 
performance of the model in independent datasets and to assess the model performance in 
predicting ovarian cancer risk in prospective studies. Future plans to extend the models 
include the addition of lifestyle and reproductive factors such as parity, breastfeeding and oral 
contraceptive use [42], mutations in genes such as RAD51C, RAD51D and BRIP1 that are 
known to be associated with OvC risk [39-41], competing causes of mortality and differences 
in the associations of the various risk factors with difference OvC morphological subtypes. 
The ultimate goal is to combine the models within the BOADICEA framework and develop a 
comprehensive breast and ovarian risk user-friendly prediction tool. 
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Titles and Legends to Figures: 
• Figure 1: Predicted risks of ovarian cancer over time to a woman born in the 
1940 birth cohort without a BRCA1 or BRCA2 mutation,  by family history. The 
predicted ovarian cancer risks under the most parsimonious model vary by extent of 
family history of ovarian cancer. In contrast, under BOADICEA the predicted ovarian 
cancer risks remain the same under all scenarios.  
• Figure 2: Lifetime risks of ovarian cancer to a 20-year-old born in the 1940 birth 
cohort without a BRCA1 or BRCA2 mutation with different PRS and FH. Graph 
of the change in probabilities of developing ovarian cancer by age 80 as PRS 
increases from -0.8 to 0.8, to a 20-year old with five different family histories. The 
two dotted lines, at -0.496 and 0.496, indicate the PRS of those at the 5th and 95th 
percentile of risk.   
• Figure 3: Proportion of population above a specified absolute risk of ovarian 
cancer and proportion of cases occurring in that fraction of the population. Half 
the population have an absolute risk of ovarian cancer greater than 0.72% by age 80 
and 92% of all cases occur in this half of the population. Half of all cancers occur in 
the 7.7% of the population with risk higher than 5.6%. 
• Figure 4: Proportion of cases accounted for by a given proportion of the 
population above a specified risk of ovarian cancer according to the total 
polygenic risk and the observed 17-SNP distribution.  Under the total polygenic 
risk distribution, 50% of cancers occur in the 7.7% of the population at highest risk 
and 92.4% of cancers occur in the half of the population at greater-than-average risk, 
whereas under the 17-SNP only 62% of cancers occur in the 50% at higher risk and 
50% of cases are spread among almost 40% of the population at highest risk. 
 
